What is Wegovy?
Wegovy Semaglutide Injection For Sale injection is used for weight loss and to lower the risk of heart attack, stroke, and cardiovascular death in specific people. Wegovy works by regulating appetite and reducing calorie intake, leading to weight loss, helping with weight management and lowering the risk of heart attacks, strokes and cardiovascular death. Wegovy is a prescription medicine given as an injection once-a-week given under the skin.
Wegovy (semaglutide)belongs to the class of drugs called GLP-1 receptor agonists. GLP-1 receptor agonists are a manufactured version of GLP-1, a naturally occurring hormone in the body that acts in several areas in the brain to regulate food intake. When Wegovy is administered, it activates the GLP-1 receptors in the brain. This lowers appetite, reducing the calories consumed and leading to weight loss.
This medicine should be used together with a decreased-calorie meal plan and increased physical activity to help weight management.
Wegovy contains semaglutide, which is the same active ingredient in Ozempic and Rybelsus, therefore these products should not be used together. Ozempic (subcutaneous weekly injection) and Rybelsus (once-a-day tablet) are used to lower blood sugar levels for type two diabetic patients. Ozempic is also used to lower the risk of major cardiovascular events for some type 2 diabetic patients.
What is Wegovy Semaglutide Injection For Sale used for?
Wegovy weight loss
Wegovy is an anti-obesity medicine that is FDA-approved to be used by people 12 years and older for chronic weight management when used together with a reduced-calorie diet and increased physical activity.
Wegovy is approved to be used for adults who are obese (BMI of 30 kg/m2 or greater) or overweight (BMI of 27 kg/m2 or greater) and have medical problems (high blood pressure, type 2 diabetes, or high cholesterol) due to your weight.
Wegovy can be used by pediatric patients (12 years and older) who are obese (initial BMI 95th percentile or greater for age and sex).
Wegovy for heart health and stroke reduction
Wegovy is FDA-approved (March 8, 2024) to reduce the risk of heart attack, stroke, and cardiovascular death in adults who are obese or overweight and have cardiovascular disease. Wegovy should be used in addition to a reduced-calorie diet and increased physical activity.
There are no reviews yet.